Mupirocin (Bactroban)

Subscribe to Selected New Research on Mupirocin

318 relevant articles (79 outcomes, 76 trials/studies) found for this Drug

Description: A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.

Also Known As:

Bactroban; BRL-4910A; Mupirocin, 14C-Labeled; Mupirocin, Calcium Salt (2:1); Mupirocin, Calcium Salt (2:1), Dihydrate; Mupirocin, Lithium Salt; Mupirocin, Sodium Salt; Pseudomonic Acid A; 14C-Labeled Mupirocin; Acid, Pseudomonic; BRL 4910A; BRL4910A; Mupirocin, 14C Labeled; Pseudomonic Acid; Nonanoic acid, 9-((3-methyl-1-oxo-4-(tetrahydro-3,4-dihydroxy-5-((3-(2-hydroxy-1-methylpropyl)oxiranyl)methyl)-2H-pyran-2-yl)-2-butenyl)oxy)-, (2S-(2alpha(E),3beta,4beta,5alpha(2R*,3R*(1R*,2R*))))-

Relationship Network

Drug Context: Research Results

Experts

1.	Chu, Kwok Hong: 2 articles (09/2008 - 01/2003)
2.	van Belkum, A: 2 articles (09/2008 - 08/2002)
3.	Cheuk, Au: 2 articles (09/2008 - 01/2003)
4.	Wenzel, Richard P: 2 articles (02/2008 - 06/2002)
5.	Kluytmans, Jan A J W: 2 articles (02/2008 - 03/2004)
6.	Bonten, Marc: 2 articles (02/2008 - 01/2008)
7.	Wong, Kok-Seng: 2 articles (10/2005 - 08/2005)
8.	Lim, Christopher Thiam-Seong: 2 articles (10/2005 - 08/2005)
9.	Vos, Margreet C: 2 articles (06/2005 - 03/2004)
10.	Wertheim, Heiman F L: 2 articles (06/2005 - 03/2004)

Related Diseases

1.	Infection 08/01/1989 - "This study suggests that mupirocin is a safe and effective topical preparation for treating most of our common skin infections." 08/01/1989 - "Mupirocin, a new antibiotic, has proved in vitro and in vivo to be highly effective in the treatment of MRSA infections. " 05/01/1988 - "Mupirocin ointment, a new topical antibiotic, has proved in vitro and in vivo to be highly effective in the treatment of MRSA infections. " 07/01/1995 - "Mupirocin (2% ointment) has also proven effective for topical treatment of these infections. " 11/01/1986 - "Mupirocin 2% ointment administered 2 or 3 times daily has shown excellent efficacy in both primary and secondary superficial skin infections, usually with at least 80% of patients being clinically cured or markedly improved, and over 90% eradication of the bacterial pathogen involved. " Order ALL the reference details at left...
2.	Impetigo 07/01/1989 - "Mupirocin is a new, topical antibiotic effective for the treatment of impetigo. " 05/01/1990 - "Randomized, multicenter, double-blind, vehicle-controlled clinical trials have shown that mupirocin is safe and effective for the treatment of impetigo." 08/01/1989 - "These results show topical mupirocin to be a safe and effective alternative to oral antibiotic therapy in the treatment of impetigo." 12/01/1988 - "Thus, mupirocin appears to be safe and effective in treating impetigo in children. " 12/01/1986 - "Initial studies comparing mupirocin to inactive vehicle in the treatment of impetigo indicate an overall 92 percent pathogen eradication rate with active drug and 58 percent eradication rate with vehicle. " Order ALL the reference details at left...
3.	Wound Infection (Wound Infections) 02/01/2008 - "CONCLUSION: Topical mupirocin application was effective against crush wound infections inoculated with S. " 08/01/2008 - "A formulation of REP8839 has demonstrated efficacy in a porcine partial thickness wound infection model against mupirocin-resistant S. " 10/01/1985 - "The efficacy of topically-applied mupirocin was evaluated against an experimental surgical staphylococcal wound infection in the guinea-pig. " 07/01/2007 - "The purpose of this study was to investigate the mupirocin resistance in MRSA strains isolated from wound infections of in- and out-patients of two distinct hospitals located in Ankara and Istanbul. " 05/01/2001 - "BACKGROUND: This study was designed to determine whether decreasing nasal bacterial colonization by applying Mupirocin (MPN) intranasally decreases sternal wound infections. " Order ALL the reference details at left...
4.	Peritonitis 10/01/2005 - "CONCLUSIONS: Our study, although retrospective, has demonstrated that the topical use of mupirocin was associated with a significant reduction in ESI and peritonitis and, unexpectedly, with findings of fewer incidences of Pseudomonas peritonitis. " 08/01/2005 - "CONCLUSIONS: Our study, although limited by its retrospective nature, demonstrated that topical mupirocin was associated with a significant reduction in ESI and peritonitis with unexpected findings of lower Pseudomonas peritonitis. " 09/01/2005 - "Local application of mupirocin led to a significant reduction in the incidence density per patient-month of both ESI and peritonitis compared to controls (0.15 vs 0.37 and 0.37 vs 0.67, p = 0.01 for both). " 03/01/2004 - "Although the overall incidence of peritonitis did not change (0.28 vs. 0.26; p=0.7) there was a significant reduction in peritonitis caused by staphylococcus aureus (0.07 vs. 0; p=0.01) Although only one catheter required removal in the mupirocin group as against 5 in the control group, this was not statistically significant. " 12/01/2007 - "Pseudomonas-based peritonitis was eightfold more common in the United States than in Europe, and correlated with the frequency of exit site cleansing and topical mupirocin administration. " Order ALL the reference details at left...
5.	Wounds and Injuries (Trauma) 08/01/1989 - "Mupirocin eliminated MRSA in all 59 wounds treated, with the maximum therapeutic response seen within 4 days. " 05/01/2009 - "METHODS: 370 subjects will be randomized 1:1 to receive either daily topical exit-site application of Medihoney Antibacterial Wound Gel (all patients) or nasal application of mupirocin if staphylococcal nasal carriage is demonstrated. " 09/01/2008 - "aureus in their wound was 0.48 (95% CI: 0.24-0.97) in the mupirocin period and 0.55 (95% CI: 0.28-1.1) during the C2 period. " 08/01/2006 - "In view of the risk of antibiotic resistance, mupirocin ointment is not indicated for clean surgical wounds." 01/15/2003 - "Culture of nares samples from the family dog grew mupirocin-resistant (minimum inhibitory concentration >1024 microg/mL) MRSA that had a pulsed-field gel electrophoresis chromosomal pattern identical to the MRSA isolated from the patient's nares and his wife's wound. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Mupirocin (Bactroban)
2.	Vancomycin
3.	Erythromycin (Erycette)
4.	Erythromycin Ethylsuccinate (E-Mycin E)
5.	Rifampin (Rifampicin)
6.	Methicillin (Metin)
7.	Fusidic Acid (Fucithalmic)
8.	Cephalexin (Cefalexin)
9.	Calcium
10.	Ointments (Pastes)

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Peritoneal Dialysis
3.	Baths
4.	Transplantation (Transplant Recipients)
5.	Continuous Ambulatory Peritoneal Dialysis (CAPD)

Best Treatments:
Research Summary Report
on Infection

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 14726 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>